Severe COVID-19 in the context of a vaccinated population: Case-control study
DOI:
https://doi.org/10.17058/reci.v14i1.19005Keywords:
COVID-19 Vaccines, Mass Vaccination, Patient AcuityAbstract
Background and Objectives: Since its appearance in 2019, multiple risk factors have been identified for presenting a severe form of COVID-19 and different vaccines have also been developed to prevent severe manifestations. However, despite a vaccination history, some cases progress to complications or even death. The objective of this study was to determine the strength of the association between the severity of COVID-19 and the history of vaccination in patients treated at a public reference hospital in Mexico City. Methods: This was a non-experimental, retrospective, and analytical epidemiological study of cases and controls. The study population was people treated at a concentration hospital for COVID-19 care between July 1, 2021, and June 30, 2022, in Mexico City. Results: 132 participants (44 cases and 88 controls) were included in the study. The risk factors most strongly associated with COVID-19 severity were age greater than or equal to 60 years, presenting 22 breaths per minute at the first medical evaluation, systolic blood pressure greater than or equal to 140 millimeters of mercury, and a history of at least one chronic comorbidity. However, vaccination history was associated with 94% (OR 0.06) lower odds of developing severe COVID-19 compared to those without a history of vaccination, regardless of the presence of associated risk factors. Conclusion: Lacking a history of vaccination and presenting any of the identified risk factors confer higher odds of developing severe forms of the disease.
Downloads
References
Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):1. doi:10.1038/S41579-020-00459-7
Hui DS, I Azhar E, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis. 2020;91:264. doi:10.1016/J.IJID.2020.01.009
Ochani RK, Kumar Ochani R, Asad A, et al. COVID-19 pandemic: from origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Le Infez Med n. 2021;20:20–36.
OPS. Evaluación de la efectividad de las vacunas contra la COVID-19 orientación provisional.; 2021. Consultado marzo 24, 2022. https://iris.paho.org/handle/10665.2/54270
Gao Y dong, Ding M, Dong X, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428–455. doi:10.1111/ALL.14657
Secretaría de Salud. 78% de población adulta en México cuenta con al menos una vacuna contra COVID-19 | Secretaría de Salud | Gobierno | gob.mx. 78% de población adulta en México cuenta con al menos una vacuna contra COVID-19. Published el 20 de octubre de 2021. Consultado septiembre 18, 2022. https://www.gob.mx/salud/prensa/78-de-poblacion-adulta-en-mexico-cuenta-con-al-menos-una-vacuna-contra-covid-19
Secretaría de Salud. Política nacional de vacunación contra el virus SARS-CoV-2, para la prevención de la COVID-19 en México. Documento Rector. 2021 p. 1–68. https://coronavirus.gob.mx/wp-content/uploads/2021/04/28Abr2021_13h00_PNVx_COVID_19.pdf
Secretaría de Salud. Información de la vacuna – Vacuna Covid. Consultado mayo 2, 2022. http://vacunacovid.gob.mx/wordpress/informacion-de-la-vacuna/
OMS. COVAX: colaboración para un acceso equitativo mundial a las vacunas contra la COVID-19 [Internet]. [citado el 10 de febrero de 2024]. Disponible en: https://www.who.int/es/initiatives/act-accelerator/covax
Gobierno de la Ciudad de México. INFORME COVID-19 30 de diciembre de 2021.; 2021. https://www.salud.cdmx.gob.mx/storage/app/uploads/public/61f/d90/dce/61fd90dce4f2f151470382.pdf
Secretaría de Salud. COVID-19 México. Informe Técnico Diario 1 de Julio de 2021.; 2021. https://www.gob.mx/cms/uploads/attachment/file/649747/Comunicado_Tecnico_Diario_COVID-19_2021.07.01.pdf
Secretaría de Salud. Informe Técnico Diario COVID-19 México 30 de junio 2022.; 2021. https://www.gob.mx/cms/uploads/attachment/file/738376/Informe_Tecnico_Diario_COVID-19_2022.06.30.pdf
Tenforde MW, Patel MM, Ginde AA, et al. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. medRxiv. Published online el 8 de julio de 2021. doi:10.1101/2021.07.08.21259776
Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021;21(11):1539. doi:10.1016/S1473-3099(21)00330-3
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412–1423. doi:10.1056/NEJMOA2101765
Thiruvengadam R, Awasthi A, Medigeshi G, et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2022;22(4):473. doi:10.1016/S1473-3099(21)00680-0
Rearte A, Castelli JM, Rearte R, et al. Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study. Lancet (London, England). 2022;399(10331):1254. doi:10.1016/S0140-6736(22)00011-3
Harrison AG, Lin T, Wang P. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis. Trends Immunol. 2020;41(12):1100. doi:10.1016/J.IT.2020.10.004
Singer M, Deutschman CS, Seymour C, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801–810. doi:10.1001/JAMA.2016.0287
Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):893. doi:10.1016/S1470-2045(20)30309-0
Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–118. doi:10.1016/J.JACI.2020.04.006
Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/JAMA.2020.1585
Guan W jie, Ni Z yi, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032
Tonelli P, Parada Lezcano M, Ismael B. La pandemia por COVID 19: el derecho a la salud en tensión. Un estudio cualitativo exploratorio en Chile, Colombia, Costa Rica y México [Internet]. 2021. Disponible en: https://www.flacso.org/sites/default/files/2022-03/la_pandemia_por_covid19.pdf
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Irving Díaz Muñoz, Oswaldo Sinoe Medina-Gómez, Gonzalo Ivan Julian-Bello
This work is licensed under a Creative Commons Attribution 4.0 International License.
The author must state that the paper is original (has not been published previously), not infringing any copyright or other ownership right involving third parties. Once the paper is submitted, the Journal reserves the right to make normative changes, such as spelling and grammar, in order to maintain the language standard, but respecting the author’s style. The published papers become ownership of RECI, considering that all the opinions expressed by the authors are their responsibility. Because we are an open access journal, we allow free use of articles in educational and scientific applications provided the source is cited under the Creative Commons CC-BY license.